The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Valemetostat and datopotamab deruxtecan in advanced NSCLC
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, provides an overview of the Phase Ib trial (NCT06244485) evaluating the safety and efficacy of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with datopotamab deruxtecan (Dato-DXd) in advanced non-small-cell lung cancer (NSCLC). The study aims to assess the safety, tolerability, and objective response rate in patients with previously treated NSCLC. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
